Stable Latent HIV Infection and Low-Level Viremia Despite Treatment with the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat

Author:

Gay, C L

James, K S

Tuyishime, M

Falcinelli, S D

Joseph, S B

Moeser, M J

Allard, B

Kirchherr, J L

Clohosey, M

Raines, S L M

Montefiori, D C

Shen, X

Gorelick,Robert

Gama, L

McDermott, A B

Koup, R A

Mascola, J R

Floris-Moore, M

Kuruc, J D

Ferrari, G

Eron, J J

Archin, N M

Margolis, D M
Author Address

University of North Carolina HIV Cure Center, UNC Chapel Hill School of Medicine, Chapel Hill, NC,USA., Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC,USA., Department of Surgery, Duke University Medical Center, Durham, USA., Department of Microbiology and Immunology, UNC Chapel Hill School of Medicine, Chapel Hill, NC,USA., UNC Center for AIDS Research, UNC Chapel Hill School of Medicine, Chapel Hill, NC,USA., AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, USA., Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USA.,

Abstract:

We tested the combination of a broadly neutralizing HIV antibody with the latency reversal agent vorinostat (VOR). Eight participants received two month-long cycles of VRC07-523LS with VOR. Low-level viremia, resting CD4+ T cell-associated HIV RNA (rca-RNA), intact proviral DNA assay (IPDA), and quantitative viral outgrowth assay (QVOA) were measured at baseline and post-treatment. In three participants, IPDA and QVOA declines were accompanied by significant declines of rca-RNA. However, no IPDA or QVOA declines clearly exceeded assay variance or natura decay. Increased resistance to VRC07-523LS was not observed. This combination therapy did not reduce viremia or the HIV reservoir. © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

See More

Author Address